Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand.
about
Human embryonic stem cell-derived neurons as a tool for studying neuroprotection and neurodegenerationNeuroprotection for stroke: current status and future perspectivesMitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategiesA high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damageRasd1, a small G protein with a big role in the hypothalamic response to neuronal activationMechanisms of lead and manganese neurotoxicityInhibition of N-Methyl-D-aspartate-induced Retinal Neuronal Death by Polyarginine Peptides Is Linked to the Attenuation of Stress-induced Hyperpolarization of the Inner Mitochondrial Membrane PotentialExtrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEPApolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factorsCell Permeable Peptides: A Promising Tool to Deliver Neuroprotective Agents in the Brain.Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species.Activin/Nodal inhibition alone accelerates highly efficient neural conversion from human embryonic stem cells and imposes a caudal positional identity.{EXPRESS] Endocytosis of GluN2B-containing NMDA receptors mediates NMDA-induced excitotoxicity.Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD.Postsynaptic density-93 deficiency protects cultured cortical neurons from N-methyl-D-aspartate receptor-triggered neurotoxicityAlterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.Neuronal Damage Induced by Perinatal Asphyxia Is Attenuated by Postinjury Glutaredoxin-2 AdministrationLack of neuroprotection of inhibitory peptides targeting Jun/JNK after transient focal cerebral ischemia in spontaneously hypertensive rats.Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.Selective regulation of NR2B by protein phosphatase-1 for the control of the NMDA receptor in neuroprotection.Lead exposure during synaptogenesis alters NMDA receptor targeting via NMDA receptor inhibitionRetinoid-independent motor neurogenesis from human embryonic stem cells reveals a medial columnar ground state.Coupling of the NMDA receptor to neuroprotective and neurodestructive events.Enhanced nitric oxide production during lead (Pb²⁺) exposure recovers protein expression but not presynaptic localization of synaptic proteins in developing hippocampal neurons.Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia.Comparative impact of voltage-gated calcium channels and NMDA receptors on mitochondria-mediated neuronal injury.TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive mannerThe subtype of GluN2 C-terminal domain determines the response to excitotoxic insults.Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonistCalcium-dependent mitochondrial function and dysfunction in neurons.Investigating the utility of human embryonic stem cell-derived neurons to model ageing and neurodegenerative disease using whole-genome gene expression and splicing analysis.Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1.Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicityEvidence for evolutionary divergence of activity-dependent gene expression in developing neuronsExtended therapeutic window of a novel peptide inhibitor of TRPM2 channels following focal cerebral ischemia.Molecular neurobiology of lead (Pb(2+)): effects on synaptic function.Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Influence of GluN2 subunit identity on NMDA receptor function.Emerging neuroprotective drugs for the treatment of acute ischaemic stroke.GluN2A versus GluN2B: twins, but quite different.
P2860
Q24308814-08A1B29E-D859-4DE5-AD4E-E70E6F19A2E4Q26853031-A8BA4D91-34FA-458E-9EDF-6CF8C35A74E1Q27024426-A7B235B8-7808-4E0B-8191-0E0D72E85C8FQ27677328-E7F6BB3F-66A8-4F8C-B980-77730FF7676EQ28271807-05012DBB-62EC-44F2-A3C3-3A48DF6905B4Q28388379-DF77DE3A-6C4A-42B0-A411-0BD2C9550C37Q28388814-69891036-51D7-4C3E-B829-4D4AA8D31125Q28567752-0DFB1452-0E57-4026-8293-3731562E2589Q28576453-9D7530AB-F00A-4B4B-9852-E80CF85E493CQ30437957-6DC8FE8F-BA9F-4F8C-BE41-7E30CE8D87ECQ31031847-E484CDCB-4FDD-4608-AB41-B4D459E30E35Q33508812-BB01DCBD-636E-490B-B736-49CF0CCE00A8Q33563187-F0B777EE-4DDC-4BC6-82D2-F9549314692EQ33591507-8A0A10B1-4615-4497-A57F-191B10192483Q33755499-4C91B122-0C4F-4029-B976-0D77336D1BB1Q33786465-32E85ECB-C361-450A-BF70-149ECE140116Q33863777-D5E77BE7-1B4F-41B9-9168-17BD573AE429Q34039925-0B967665-9231-4C14-9422-152E685D27C7Q34138025-9D50CF6B-80FC-4C54-9377-ABECF45AE3B8Q34222014-D41256AE-33B0-41A2-BA01-BC802F9E0B84Q34629240-0AD53FD4-2F91-4F57-8095-8D4AB3D9C08FQ34768963-B513C735-F54F-43E2-A83C-A75328BFA4A4Q35012580-C981D596-6D77-4BD1-B78B-701A6A58DA50Q35740196-CA324FDB-C6A2-478B-9731-344D35B80B30Q35760215-10204F6E-E195-48FA-AC47-FA9D0FD3D459Q36018983-3C9F9306-BAC4-44BB-838D-E58CF0B908BBQ36060938-F72A8C2A-F926-4BE2-B2F1-A9485718DC28Q36099382-9C33DB74-C849-4081-A762-C553D59B802EQ36158931-83EBC61C-6F82-4FD4-B5D1-E19221C6767EQ36372727-1A4A0B2C-833A-4AF9-95A8-F8F4F463D0AFQ36417107-98E57BAE-9A77-41C1-A510-9E2FB20CB02FQ36569944-A770A8B4-E5EE-4BE5-9466-C8448B07D772Q37239075-EE2F7FF3-0862-4F71-8095-C32A8BC74155Q37388688-4D4AC04B-D29A-44B9-BC48-47514E9D16ABQ37589003-F38EAB0E-12D3-4701-8934-B23BFB2FE4A2Q37806164-FE1CF7D1-7026-4E38-AE60-34A460D39BA9Q37930190-0686AB3F-8986-4E24-8F53-8EA5B1FA4021Q38078685-202DA5E3-3FC3-4A64-BA56-D70CB4408866Q38100263-53B52383-0B28-4821-974F-64F48BED4E68Q38100646-E8CD7113-7E7E-4860-A5FC-4254E43AF709
P2860
Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Specific targeting of pro-deat ...... liance on the NR2B PDZ ligand.
@en
Specific targeting of pro-deat ...... liance on the NR2B PDZ ligand.
@nl
type
label
Specific targeting of pro-deat ...... liance on the NR2B PDZ ligand.
@en
Specific targeting of pro-deat ...... liance on the NR2B PDZ ligand.
@nl
prefLabel
Specific targeting of pro-deat ...... liance on the NR2B PDZ ligand.
@en
Specific targeting of pro-deat ...... liance on the NR2B PDZ ligand.
@nl
P2093
P2860
P50
P1476
Specific targeting of pro-deat ...... liance on the NR2B PDZ ligand.
@en
P2093
Anne Vaslin
Joan Forder
Marc-Andre Martel
Michael Tymianski
Paul Baxter
Peter Clarke
Sofia Papadia
P2860
P304
10696-10710
P356
10.1523/JNEUROSCI.1207-08.2008
P407
P577
2008-10-01T00:00:00Z